Emergent BioSolutions (NYSE:EBS) Shares Up 7.9% After Analyst Upgrade

Emergent BioSolutions Inc. (NYSE:EBS - Get Free Report) shares rose 7.9% on Friday after Benchmark raised their price target on the stock from $8.00 to $12.00. Benchmark currently has a buy rating on the stock. Emergent BioSolutions traded as high as $11.96 and last traded at $11.87. Approximately 354,196 shares traded hands during trading, a decline of 90% from the average daily volume of 3,398,985 shares. The stock had previously closed at $11.00.

Separately, Rodman & Renshaw restated a "buy" rating and issued a $16.00 price target on shares of Emergent BioSolutions in a research note on Friday, September 13th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in EBS. CWM LLC increased its position in Emergent BioSolutions by 32,706.7% during the 2nd quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 4,906 shares during the period. Tidal Investments LLC bought a new stake in Emergent BioSolutions during the 1st quarter worth approximately $34,000. Meeder Asset Management Inc. bought a new position in Emergent BioSolutions during the 2nd quarter worth $41,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Emergent BioSolutions in the first quarter worth approximately $57,000. Finally, Price T Rowe Associates Inc. MD raised its stake in Emergent BioSolutions by 22.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 23,943 shares of the biopharmaceutical company's stock worth $61,000 after buying an additional 4,409 shares during the last quarter. 78.40% of the stock is owned by institutional investors and hedge funds.

Emergent BioSolutions Price Performance

The company has a debt-to-equity ratio of 1.16, a quick ratio of 0.54 and a current ratio of 1.06. The business has a 50 day moving average price of $8.36 and a 200-day moving average price of $7.67. The company has a market capitalization of $623.24 million, a price-to-earnings ratio of -2.87 and a beta of 1.57.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($1.35). The company had revenue of $254.70 million for the quarter, compared to analysts' expectations of $199.47 million. Emergent BioSolutions had a negative net margin of 53.26% and a negative return on equity of 34.38%. During the same period in the previous year, the firm earned ($1.06) EPS. Research analysts predict that Emergent BioSolutions Inc. will post -1.3 EPS for the current fiscal year.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.